

21 March 2025

BIOXYNE RECEIVES FIRM COMMITMENTS TO RAISE \$3 MILLION IN CAPITAL RAISE

Australian life sciences, pharmaceutical and consumer health products Company, **Bioxyne Limited** (ASX Code: BXN) ("Bioxyne" or the "Company") is pleased to advise that it has received firm commitments to raise \$3 million in capital raise. The raise was well supported by new and existing institutional shareholders and sophisticated investors, both domestic and international.

The Company will issue 120,000,000 new Shares at \$0.025 per share under the Company's Listing Rule 7.1A capacity. The price is a 2.2% discount to the 15 day Volume Weighted Average Price of \$0.0256 at the close of trading on Tuesday, 18 March 2025.

In addition, the Company will issue 60,000,000 options on the basis of one option for every two new Shares, with exercise price \$0.05 and expiry date two years from the date of issue, to be issued out of the Company's Listing Rule 7.1 capacity.

The funds will be used to support expansion into European markets and the set up and certification of medical cannabis manufacturing facilities in the United Kingdom and Czechia. Funding will also enable BXN to accelerate its growth strategy and deliver upon its stated revenue guidance of \$25 million for FY25.

The directors will participate in the amount of \$110,000, subject to shareholder approval at the next meeting of shareholders.

Alpine Capital Pty Limited acted as Sole Lead Manager and Bookrunner to the Placement. Brokers and advisors will be issued 24 million options with exercise price of \$0.0437 and expiry date two years from date of issue and a further 3 million options with exercise price of \$0.01 and expiry date two years from date of issue, for services rendered.

Sam Watson, Bioxyne CEO commented, *"we are delighted with the support of institutional and sophisticated investors for this capital raise. While we received demand for well in excess of the amount raised, given that we are profitable and cash flow positive, we are of the view that it was important to limit the raise to the funds required for expansion as outlined in our strategic plan".*

This announcement has been approved for release by the Board.

For further information contact:

Sam Watson
Managing Director
Bioxyne Limited
sam@breathelifesciences.com

Guy Robertson
Chief Financial Officer
Bioxyne Limited
guy@bioxyne.com




info@bioxyne.com



+61 2 9078 8180



Suite 506, Level 5 50 Clarence
Street, Sydney NSW 2000



Bioxyne Activity Worldwide



About Bioxyne Ltd.

Bioxyne Limited (ASX:BXN) is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

About Breathe Life Sciences (BLS)

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, sponsor, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA..

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. Our corporate head office is in Sydney, and our operations extend to licensed manufacturing, warehousing, import/export, sales and distribution centers in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

Our business model is focused on manufacturing final dose form finished products, sales and distribution in each of the territories we serve. We work with raw materials and API suppliers in 5 continents and are a market leader in the manufacture of novel / investigational therapeutic goods. .

The BLS logo is derived from a Japanese Maple Leaf, symbolising health, happiness and a long life well lived. While the Japanese Maple is not a medicinal plant, our company purpose is to redefine medicine by taking a holistic approach to healthcare for a healthier and happier tomorrow. Outside of Australia the BLS Group operates a health and wellness products and brands business focussed on naturally derived active nutraceuticals, wellness and lifestyle supplements and cannabidiol (CBD) based novel foods. It primarily operates in the UK, Europe and Japan, and engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand – Dr Watson is an internationally recognized health, lifestyle, and prescription products brand. Dr Watson products consist of cannabis-based food supplements, lifestyle products, cosmetics, functional mushrooms and nootropics, and prescription medicines in Australia;
- b) Contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe;
- c) White label manufacture of third-party wellness and supplements brands in Japan, UK and Europe in company-owned facilities;
- d) Research and development; and
- e) Direct sales via online and wholesale sales of BLS-owned consumer brands, such as Dr Watson®
 - **United Kingdom:** drwatsoncbd.com
 - **Japan:** nolcbrn.com
- f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets.

Corporate: <https://bioxyne.com>

Australia: <https://bls.com.au>;

International: <https://breathelifesciences.com>

